4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding 4D Molecular Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 126 | 121 | −5 |
| Shares | 43.1M | 40.4M | −2.69M (−6.2%) |
| Value | $139.8M | $149.9M | +$10.0M (+7.2%) |
New holders (17)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Gsa Capital Partners LLP | 117,719 | $437.0K | 0.03% |
| XTX Topco Ltd | 78,580 | $291.5K | 0.01% |
| Norges Bank | 54,219 | $201.2K | 0.00% |
| Squarepoint Ops LLC | 52,879 | $196.2K | 0.00% |
| Kera Capital Partners, Inc. | 24,068 | $89.3K | 0.02% |
| Rangeley Capital, LLC | 13,000 | $48.2K | 0.06% |
| Virtu Financial LLC | 12,648 | $47.0K | 0.00% |
| Los Angeles Capital Management LLC | 11,280 | $41.8K | 0.00% |
| Quadrature Capital Ltd | 11,257 | $41.8K | 0.00% |
| Meeder Asset Management Inc | 5,923 | $22.0K | 0.00% |
| Highline Wealth Partners LLC | 3,000 | $11.1K | 0.00% |
| Farther Finance Advisors, LLC | 2,278 | $8.45K | 0.00% |
| Clear Street Markets LLC | 977 | $3.63K | 0.00% |
| Caitong International Asset Management Co., Ltd | 546 | $2.03K | 0.00% |
| Allworth Financial LP | 150 | $557 | 0.00% |
| Fifth Third Bancorp | 110 | $408 | 0.00% |
| Essential Partners LLC | 101 | $375 | 0.00% |
Sold out (22)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.